KRRO vs MGNX

Key Takeaways

• Korro Bio (KRRO) is a clinical-stage RNA-editing biotech with a market cap of approximately $155 million, while MacroGenics (MGNX) is an oncology-focused antibody therapeutics company valued near $254 million.
• Both companies have extended their cash runways into late 2027, but MGNX generates substantially more collaboration revenue (TTM of roughly $157 million vs. KRRO's approximately $4 million), reflecting a more mature partnering infrastructure.
• KRRO has exhibited significantly higher volatility, with a beta of 2.11 versus MGNX's 1.18, making it a more speculative holding within the biotech space.
• Analyst consensus is more bullish on KRRO (Strong Buy, $20.00 price target implying ~87% upside) than MGNX (Buy, $6.75 target implying ~69% upside), though both targets reflect considerable optimism.
• Year-to-date performance diverges sharply: MGNX has surged approximately 148% while KRRO has gained roughly 46%, though KRRO trades far below its 52-week high of $55.89.

Introduction

Biotechnology stocks often attract investors who are comfortable with elevated risk in exchange for potentially transformative returns, and both Korro Bio and MacroGenics sit squarely in that category. These two clinical-stage companies operate at different intersections of drug development — one pursuing a novel RNA-editing platform for genetic diseases, the other advancing a portfolio of antibody-based cancer therapies — yet they share the same capital-intensive reality of pre-revenue biotech investing. This comparison breaks down their recent performance, business models, risk profiles, and the signals that quantitative trading systems may be reading from each name. For traders and investors evaluating exposure to the biotech sector, understanding the contrasts between KRRO and MGNX offers a useful lens on the dynamics shaping small- to mid-cap drug developers in the current market.

KRRO Overview and Recent Performance

Korro Bio, Inc., headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines through its proprietary RNA-editing platform. The company's approach — editing RNA rather than DNA — aims to deliver precise, transient single-base edits with potentially improved safety and tunability compared to permanent DNA-level modifications. Korro's lead program, KRRO-110, is in a Phase 1/2a REWRITE clinical trial targeting Alpha-1 Antitrypsin Deficiency (AATD), a genetic condition affecting the liver and lungs. The company also recently nominated KRRO-121, designed to create a de novo protein variant for patients with hyperammonemia — a condition involving elevated ammonia levels in the blood — and maintains a collaboration agreement with Novo Nordisk targeting cardiometabolic diseases.

In recent months, KRRO shares have experienced pronounced volatility. The stock traded near $14 in early July 2026 before declining into the $10–$11 range by late July, extending a pullback from its 52-week high of $55.89. Sentiment has been shaped by a mix of pipeline progress and recalibrated expectations. In November 2025, the company reported that KRRO-110 produced functional protein in AATD patients but did not reach projected levels following a single administration, prompting a strategic pivot to a GalNAc (N-acetylgalactosamine) delivery approach. Korro ended the third quarter of 2025 with $102.5 million in cash and implemented a restructuring to extend its runway into the second half of 2027. With a beta of 2.11, the stock remains notably sensitive to broader market swings and binary clinical events. The analyst consensus remains a Strong Buy with a 12-month price target of $20.00, reflecting confidence in the platform's longer-term potential despite near-term headwinds.

MGNX Overview and Recent Performance

MacroGenics, Inc., based in Rockville, Maryland, is a biopharmaceutical company specializing in the discovery, development, and commercialization of monoclonal antibody-based therapeutics for cancer. The company generates its pipeline from a proprietary suite of next-generation antibody technology platforms, including bispecific DART (Dual-Affinity Re-Targeting) molecules and antibody-drug conjugates (ADCs), which are engineered antibodies that deliver toxic payloads directly to cancer cells. Its lead clinical candidate, lorigerlimab, is a bispecific DART molecule targeting PD-1 and CTLA-4 checkpoint inhibitors, in development for ovarian cancer after the company recently discontinued its prostate cancer program for the same asset. Other pipeline programs include MGC026 (a B7-H3-targeting ADC) and MGC028 (an ADAM9-targeting ADC) for solid tumors. MacroGenics has also established a track record of monetizing assets: TZIELD was sold to Provention Bio (now Sanofi), ZYNYZ was licensed to Incyte, and MARGENZA was sold to TerSera Therapeutics.

MGNX shares have staged a remarkable recovery in recent months. The stock entered 2026 trading around $1.61 and reached levels above $4.50 by mid-July 2026, representing a year-to-date gain of approximately 148%. This upward trajectory has been supported by tangible financial catalysts. In the third quarter of 2025, the company achieved $75 million in additional partnering proceeds from Sanofi and Gilead, and granted a license to an additional preclinical program leveraging its T-cell engager platform. As of September 30, 2025, MacroGenics held $146.4 million in cash and marketable securities, with the additional $75 million in expected payments extending its runway into late 2027. The company's trailing twelve-month (TTM) revenue, a rolling metric that captures the most recent four quarters, stands at approximately $157 million — substantially higher than most peers at a similar clinical stage, reflecting its active collaboration and contract manufacturing revenue streams. With a beta of 1.18, MGNX exhibits lower systematic risk relative to the broader biotech universe. Analyst consensus is a Buy rating with a 12-month price target of $6.75.

Trending AI Robots

For traders seeking a data-driven edge in navigating volatile stocks like these, Tickeron's Trending AI Robots page offers a curated selection of AI-powered trading bots designed to adapt to shifting market conditions. Tickeron maintains hundreds of AI trading bots that collectively trade thousands of different tickers, but only a subset earns placement in the Trending AI Robots section — those demonstrating the strongest alignment with current market dynamics. These bots span diverse trading styles, from short-term momentum strategies to longer-duration swing trading approaches, each with distinct performance statistics, win rates, and trade frequencies. Whether a trader is interested in biotech volatility plays or steadier sector rotation strategies, the curated list provides a starting point for exploring algorithmic trading solutions. Visit the Trending AI Robots page to explore which bots are currently trending and evaluate whether their strategies align with your market outlook.

Head-to-Head Comparison

While both KRRO and MGNX operate in the biotechnology sector, their business models and market positioning diverge in several important respects. Korro Bio is an earlier-stage platform company built around a single core technology — RNA editing — with a narrower pipeline and correspondingly higher binary risk tied to clinical readouts. MacroGenics, by contrast, has a broader and more diversified oncology pipeline backed by multiple proven technology platforms, and it has demonstrated an ability to generate substantial non-dilutive capital through partnerships with major pharmaceutical companies such as Sanofi, Gilead, and Incyte.

In terms of financial scale, the contrast is stark. MGNX's TTM revenue of approximately $157 million dwarfs KRRO's roughly $4 million, giving MacroGenics a more robust buffer against the cash-burn pressures inherent to drug development. Both companies project cash runways into late 2027, but MGNX achieves this with a significantly larger operating base. On valuation, KRRO trades at a market cap of roughly $155 million against a $20.00 analyst price target, while MGNX commands approximately $254 million with a $6.75 target — reflecting different market expectations about each company's addressable opportunity.

Risk profiles also differ meaningfully. KRRO's beta of 2.11 signals considerably higher sensitivity to market movements than MGNX's 1.18, and Korro's 52-week range — spanning from $5.20 to $55.89 — underscores the magnitude of price swings that have occurred. MGNX's 52-week range of $1.29 to $5.08, while wide in percentage terms, reflects a stock that has been steadily rebuilding from a deep trough. Sector exposure also sets the two apart: Korro's genetic medicine focus places it at the frontier of a still-nascent therapeutic modality, while MacroGenics competes in the more established — and crowded — oncology antibody space, where partnering deal flow and clinical differentiation are critical determinants of success.

Tickeron AI Verdict

Based on observable trend consistency, relative financial positioning, and momentum characteristics, Tickeron's AI-driven analytical framework would likely assign a near-term edge to MGNX over KRRO in the current market environment. MacroGenics benefits from a more diversified revenue base, confirmed partnership inflows that strengthen its balance sheet, and a steadier uptrend that has carried the stock substantially higher year-to-date without the extreme drawdowns from prior highs that characterize Korro's chart. The lower beta and higher TTM revenue provide a stability profile that algorithmic models typically favor when evaluating risk-adjusted momentum. That said, KRRO's significantly higher analyst upside target and its novel RNA-editing platform represent potential catalysts that could shift relative positioning if clinical data or partnership announcements alter the risk-reward calculus. As with all probabilistic assessments, these signals reflect current observable data and may evolve as new information emerges.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations